This result is consistent with previous studies showing that baseline ANG-2 levels are significantly associated with a poor response to lenvatinib in patients with unresectable HCC [11] and a shorter PFS in patients with advanced medullary thyroid cancer [17]. This evidence concerns the gene ANGPT2 and hepatocellular carcinoma.